Logo

Bio-Thera Expands its Partnership with Pharmapark to Commercialize BAT2206 (biosimilar- ustekinumab in Russia and other CIS Countries

Share this

Bio-Thera Expands its Partnership with Pharmapark to Commercialize BAT2206 (biosimilar- ustekinumab in Russia and other CIS Countries

Shots:

  • Pharmapark to get exclusive rights to commercialize the therapy with a status of a local product & will be responsible for filing the report in Russia and other CIS countries
  • The agreement will utilize Pharmapark’s sales and marketing capabilities for the ustekinumab biosimilar program in Russia & other CIS countries. Bio-Thera will lead the development- and commercial supply of BAT2206 out of its manufacturing facilities in Guangzhou- China
  • Bio-Thera’s BAT2206 has completed a P-I study and is currently being evaluated in a P-III clinical study including patients from China- Russia- and other countries & plans to file for regulatory approval with the NMPA- EMA & FDA

  | Ref: Businesswire | Image: Businesswire

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions